Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

RenovoRx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED ITS FINANCIAL RESULTS AND BUSINESS UPDATE TO SHAREHOLDERS FOR THE SECOND QUARTER ENDED JUNE 30, 2025. WE ARE PLEASED TO REPORT SECOND QUARTER 2025 REVENUE OF OVER $400,000. THIS GROWTH HIGHLIGHTS THE STRONG CLINICAL NEED AND MARKET.

RENOVORX REPORTS COMMERCIAL REVENUE GROWTH IN THE SECOND QUARTER 2025 AND ANNOUNCES POSITIVE INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION TO CONTINUE PIVOTAL PHASE III TIGER-PAC TRIAL BASED ON INTERIM DATA REVIEW

RENOVORX INCREASES ITS COMMERCIAL FOOTPRINT TO THIRTEEN LEADING NATIONAL CANCER INSTITUTE-DESIGNATED AND COMMUNITY CENTERS APPROVED TO PURCHASE RENOVOCATH

RENOVORX EXPANDS U.S. COMMERCIALIZATION EFFORTS FOR THE RENOVOCATH DEVICE WITH GROWING CUSTOMER DEMAND AND KEY LEADERSHIP HIRE

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A PATENTED, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THE LAUNCH OF THE PANTHER POST-MARKETING REGISTRY STUDY (NCT06805461). THE INITIATION OF THIS STUDY DEMONSTRATES RENOVORX'S COMMITMENT TO INNOVATION AND RENOVOCATH'S CURRENT AND FUTURE POTENTIAL. THE STUDY WILL SERVE AS A CRITICAL.

RENOVORX LAUNCHES MULTI-CENTER POST-MARKETING REGISTRY STUDY TO EVALUATE CANCER TREATMENT DELIVERED BY RENOVOCATH DEVICE TO SOLID TUMORS

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED IT WILL HOST ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON AUGUST 14, 2025, AT 4:30 P.M. ET. ADDITIONAL DETAILS WILL BE AVAILABLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT H.

RENOVORX TO HOST SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS CONFERENCE CALL ON AUGUST 14TH AT 4:30 P.M. ET

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED ITS FINANCIAL RESULTS AND BUSINESS UPDATES FOR THE FIRST QUARTER ENDED MARCH 31, 2025. RENOVOCATH POWERS RENOVORX'S PATENTED TRANS-ARTERIAL MICRO-PERFUSION (TAMP) THERAPY PLATFORM. I AM PLEASED TO REPORT A MILESTONE EVENT FOR RENO.

RENOVORX REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT CHIEF EXECUTIVE OFFICER, SHAUN BAGAI, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE ALLIANCE GLOBAL PARTNERS (A.G.P.) VIRTUAL HEALTHCARE COMPANY SHOWCASE HOSTED BY SCOTT HENRY, MANAGING DIRECTOR AND HEALTHCARE ANALYST AT A.G.P., O.

RENOVORX TO PARTICIPATE IN FIRESIDE CHAT AT A.G.P. VIRTUAL HEALTHCARE COMPANY SHOWCASE ON MAY 21ST

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT IT HAS RECEIVED AN ISSUE NOTIFICATION FROM THE U.S. PATENT AND TRADEMARK OFFICE (USPTO) INDICATING THAT U.S. PATENT NO. 12,290,564, BECOMES EFFECTIVE TODAY, MAY 6, 2025. THIS PATENT, TITLED METHODS FOR TREATING TUMORS, EXPAND.

U.S. PATENT OFFICE ISSUES NEW PATENT TO RENOVORX FOR NOVEL TRANS-ARTERIAL MICRO-PROFUSION (TAMP) THERAPY PLATFORM

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED IT WILL HOST ITS FIRST QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL ON MAY 15TH, 2025, AT 4:30 P.M. ET. ADDITIONAL DETAILS WILL BE AVAILABLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT HTTPS://IR.RENOVORX.COM/. EV.

RENOVORX TO HOST FIRST QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL ON MAY 15TH AT 4:30 P.M. ET

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT JOHNS HOPKINS MEDICINE IS NOW INITIATED TO ENROLL PATIENTS WITH LOCALLY ADVANCED PANCREATIC CANCER (LAPC) IN RENOVORX'S ONGOING PHASE III TIGER-PAC CLINICAL TRIAL. JOHNS HOPKINS MEDICINE BECOMES THE NEWEST ADDITION TO A DISTING.

JOHNS HOPKINS MEDICINE INITIATES PATIENT ENROLLMENT FOR RENOVORX'S ONGOING PHASE III TIGER-PAC CLINICAL TRIAL

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT IT IS INCREASING PRODUCTION OF ITS FDA-CLEARED RENOVOCATH CATHETER-BASED DEVICE IN ORDER TO MEET INCREASED DEMAND FOR THE TARGETED DELIVERY OF DIAGNOSTIC AND/OR THERAPEUTIC AGENTS FROM ONCOLOGISTS AND INTERVENTIONAL RADIOLOGISTS.

RENOVORX INCREASES U.S. PRODUCTION OF RENOVOCATH DEVICES TO MEET GROWING DEMAND FROM ONCOLOGY COMMUNITY

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)--RENOVORX, INC. (RENOVORX OR THE COMPANY) (NASDAQ: RNXT), A LIFE SCIENCES COMPANY DEVELOPING INNOVATIVE TARGETED ONCOLOGY THERAPIES AND COMMERCIALIZING RENOVOCATH, A NOVEL, FDA-CLEARED DRUG-DELIVERY DEVICE, TODAY ANNOUNCED THAT CHIEF EXECUTIVE OFFICER SHAUN BAGAI WILL PRESENT AT THE LD MICRO INVITATIONAL XV: NEW YORK 2025 CONFERENCE TAKING PLACE AT THE WESTIN GRAND CENTRAL HOTEL, NEW YORK, NY ON APRIL 10, 2025. MR. BAGAI WILL DISCUSS RECENT CORPORATE M.

RenovoRx, Inc.

RNXT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RenovoRx, Inc.

RNXT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RNXT